B
lood vessels play essential roles in the transport of gases, nutrients, waste products, and circulating cells in the healthy organism. Although vessels are quiescent in adults, the growth of blood vessels is critical to development, growth, and regeneration. 1, 2 Angiogenesis-the formation of new blood vessels-consists of sprouting new vessels from preexisting ones and the eventual fusion of these with other sprouts or blood vessels to form new vascular connections. Vessel growth is stimulated by angiogenic factors, which are divided into (1) activators, such as VEGF-A (vascular endothelial growth factor-A; hereafter referred to as VEGF), FGF (fibroblast growth factor) 2, and EGF (epidermal growth factor), which induce endothelial cell proliferation and migration 1, 3 ; and (2) maturation factors, such as TNF-α (tumor necrosis factor-α), and some members of the TGF-β (transforming growth factor-β) family, which prompt endothelial cells to cease proliferation, reestablish basal membrane, and recruit mural cells. 4, 5 BMP (bone morphogenetic protein) 9 is a member of the TGF-β family that selectively activates ALK1 (activin receptor-like kinase)-a serine-threonine kinase type I TGF-β receptor in endothelial cells. 6 Activation of ALK1 triggers the phosphorylation of Smad1, 5, and 8, which in turn forms an active complex with Smad4, translocates to the nucleus, and stimulates the expression of genes, such as ID, endoglin, and Tmem100. [7] [8] [9] BMP9 has been proposed as limiting VEGF-and FGF-induced endothelial cell proliferation. 6, 10, 11 However, it is still unclear how ALK1 negatively regulates proangiogenic cascades. Given the inhibitory role of ALK1 during vessel growth, it is not surprising that genetic and pharmacological blockage of ALK1 in vivo results in aberrant overgrowth of the vasculature. 12, 13 Hereditary hemorrhagic telangiectasia (HHT), also known as Rendu-Osler-Weber syndrome, is a rare autosomal-dominant germline disease, with an incidence of 1:5000, characterized by the local overgrowth of the vascular plexus. 14 The telangiectasia is the common name for vascular lesions in patients with HHT 15 and consists of an artery directly connected to a vein that generates a fragile site that can easily rupture and bleed. The telangiectasias are found on the skin of the face and hands and the lining of the nose and mouth. Less common, but more severe, are the internal vascular lesions, which principally occur in lung, liver, and the digestive tract and may lead to hemorrhagic episodes, stroke, or brain abscesses secondary to pulmonary arteriovenous malformations (AVMs), or arterial aneurysms and pulmonary arterial hypertension, or high-output heart failure secondary to liver vascular malformations. 16 HHT is divided into HHT types 1 and 2 on the basis of the mutation responsible for the pathogenesis of the disease. Although HHT1 arises from inactivation mutations in ENG, the gene encoding the TGF-β coreceptor endoglin 17 HHT2 is caused by mutations in ACVRL1-the gene encoding ALK1. 18 Pulmonary and cerebral AVMs are more common in HHT1, whereas hepatic vascular malformations predominate in HHT2. Therapeutic strategies are aimed at reducing potential complications because of vascular malformations, but there is currently no curative treatment for HHT.
In this study, we used heterozygous ALK1 mouse retinas and cultured endothelial cells to study how ALK1 represses vessel growth. We found that loss of ALK1 leads to increased stalk cell proliferation as a result of overactivation of PI3K (phosphatidylinositol 3-kinase) signaling. By analyzing a small cohort of patients, we found that mutations in ALK1 result in increased activation of PI3K signaling in human telangiectasias compared with control vessels. These findings, together with the observation that blocking the PI3K signaling pathway rescues ALK1-induced vascular hyperplasia, provide the proof of concept for therapeutic intervention with PI3K inhibitors for the treatment of HHT.
Materials and Methods

Reagents
BMP9 was obtained from Sigma-Aldrich (St. Louis, MO). VEGF was obtained from R&D Systems (Minneapolis, MN). LDN-212854 was obtained from Selleckchem.com (Houston, TX) and was dissolved in dimethyl sulfoxide (DMSO). SF1670 was obtained from Echelon Biosciences (Salt Lake City, UT) and was dissolved in DMSO. Cell culture media, FCS, and antibiotics were obtained from Lonza (Basel, Switzerland) and Gibco (ThermoFisher Scientific, Waltham, MA). Other reagents were of analytic or molecular biological grade and were purchased from Sigma-Aldrich or Roche (Basel, Switzerland).
Cutaneous Telangiectasia Biopsy of Patients With HHT
Patients from the HHT Unit of Bellvitge University Hospital with mutations in ACVRL1 and who presented cutaneous telangiectasias were selected for the study. Genetic tests were performed by Health in Code (A Coruña, Spain) using next-generation sequencing. Six patients were selected consecutively, all of whom gave their signed informed consent. Severity of nosebleeds was measured according to the epistaxis severity score. 19 Abnormal findings from CT or contrast transthoracic echocardiography with agitated saline solution were also recorded. Contrast transthoracic echocardiography was scored according to the 4-category grading system proposed by Barzilai et al. 20 A punch biopsy (3 mm) from a cutaneous telangiectasia on a finger was obtained under the usual conditions of sterility and hygiene. Samples were processed directly into test tubes with formaldehyde in encrypted form according to a code assigned to each patient. The study was approved by the Clinical Research Ethics Committee of Bellvitge University Hospital.
Immunohistochemistry Studies
Biopsies were fixed in buffered formalin, dehydrated, and embedded in paraffin. Tissue sections (3-4 μm) were stained with hematoxylineosin for morphological analysis. Sections of formalin-fixed, paraffin-embedded biopsies were analyzed to determine the amount of expression of various proteins. Samples were deparaffinized in xylene and rehydrated in downgraded alcohols and distilled water. CD34 was stained after antigen retrieval performed under high-pressure conditions for 2 minutes in citrate buffer, pH 6, and incubated with 3% H 2 O 2 for 10 minutes. Samples were then blocked with 1:20 goat serum for 1 hour followed by incubation at 4°C overnight with monoclonal mouse antibody antihuman CD34 (Dako, Carpinteria, CA). Sections were incubated with the specific secondary anti-mouse antibody EnVision (Dako), followed by the DAB developing system (Dako). pAKT, pNDRG1 (N-Myc downstream regulated 1), pS6, and Ki-67 were stained after antigen retrieval performed under high-pressure conditions for 4 minutes in citrate buffer, pH 6.5, and incubated with 3% H 2 O 2 for 10 minutes. Samples were then blocked with 0.3% BSA in PBS for 1 hour followed by incubation at 4°C overnight with polyclonal rabbit antibody antiphospho-NDRG1 ( were incubated with the specific secondary anti-rabbit antibody EnVision (Dako), followed by the DAB developing system (Dako). Samples were counterstained with hematoxylin and visualized under light microscopy. For all samples, negative controls were performed, in which the section followed exactly the same protocol but in the absence of primary antibody.
Animals
Control and heterozygous ALK1 mice (strain C57BL/6) 21 were housed and maintained in laminar flow cabinets under specific pathogen-free conditions. All the animal studies were approved by the local committee for animal care (DAAM 5766; Institut d'Investigació Biomèdica de Bellvitge). Where indicated, ALK1 heterozygous animals were crossed with the p110α heterozygous animal. 22 Class I PI3K signaling was inhibited in half of the pups by subcutaneous injection at 6:00 pm in P6 and 10:00 am in P7 with 20 μL of 15 mmol/L LY294002 (Calbiochem, Millipore, Billerica, MA) dissolved in DMSO. Retinas were harvested at 2:00 pm on P7. Control mice were injected with DMSO only.
Retina Immunofluorescence
Eyes were fixed in 4% paraformaldehyde for 2 hours at 4°C. Retinas were permeabilized in PBS containing 1% BSA and 0.3% Triton X-100 overnight at 4°C, followed by incubation when indicated with polyclonal rabbit antiendothelial nuclei marker Erg-1/2/3 antibody (Cat. SC-353; Santa Cruz, CA) or polyclonal rabbit antidesmin antibody (Cat. Ab15200; Abcam, Cambridge, United Kingdom) in permeabilization buffer overnight at 4°C. The following day, the eyes were washed 3× with PBS containing 0.1% tween, once in Pblec buffer (1% Triton X-100, 1 mmol/L CaCl 2 , 1 mmol/L MgCl 2 , and 1 mmol/L MnCl 2 in PBS, pH 6.8) for 30 minutes and then incubated for 2 hours at room temperature (RT) or overnight at 4°C in Pblec buffer containing Alexa-488 or Alexa-568 conjugated secondary antibodies (1:200) and isolectin GS-IB 4 (1:300; Molecular Probes; ThermoFisher Scientific). They were washed 3 more times with PBS containing 0.1% tween and flat mounted on microscope glass slides with Mowiol. We used a Leica SP5 for fixed confocal laser scanning microscopy. Images were analyzed with Image J Software. To address specific endothelial cell proliferation, we injected 60 μL of 2 mmol/L of the proliferation marker EdU (Click-iT EdU Imaging Kit; Invitrogen, Life Technologies, MA) for 2 hours into P7 mice. After euthanization, we determined EdU-positive endothelial cells after colabeling with the endothelial nuclei marker Erg-1/2/3 and IB4 (isolectin B4), following the manufacturer's instructions.
Cell Culture
Human umbilical vein endothelial cells (HUVECs; passages 1-7) were obtained from Lonza and routinely cultured in gelatin coated (1%) in endothelial basal medium (Lonza) supplemented with 20% FCS, 50 U/mL penicillin, 50 µg/mL streptomycin sulfate, 3 µg/mL human EGF, 30 µg/mL gentamicin, 15 ng/mL amphotericin, 9 mg/ mL bovine brain extract, 25 mg/mL ascorbic acid, and 1 µg/mL hydrocortisone.
For short treatments, cells at 80% confluence were starved in M199 without FCS for 16 hours and then treated or not as indicated for various times with 10 ng/mL of BMP9 or 10 ng/mL of VEGF, depending on the experiment.
siRNA Transfection
For siRNA experiments, control (siGENOME nontargeting siRNA pool, Cat. D-001206-13-05; Dharmacon, GE Healthcare Life Sciences, Buckinghamshire, United Kingdom) or human PTEN (phosphatase and tensin homolog) siRNAs (Cat. D-003023-05-0005; Dharmacon) was diluted in Opti-MEM I at a final concentration of 80 nmol/L. Lipofectamine RNAiMAX (Cat. 13778; Invitrogen) was also diluted in Opti-MEM I in a different tube and added to the siRNA mix. After incubating for 20 minutes at RT, the transfection reagent mix was added to HUVECs in suspension (resuspended in Opti-MEM I medium containing 10% fetal bovine serum) and seeded in 6-well plates. Cells were incubated with the reaction mix for 8 hours.
At the end of the incubation, the medium was changed to complete endothelial basal medium for additional 48 hours. Cells were starved in M199 without FCS for 16 hours and then pretreated or not with 10 ng/mL of BMP9 for 4 hours and finally treated or not with 10 ng/mL of VEGF for an additional 30 minutes. For cell growth experiments, immediately after transfection, 1×10 4 cells were seeded in 24-well plastic plates (Corning, NY). The next day, the medium was changed to M199 with 0.5% FCS, and the cells were treated or not with 10 ng/ mL of BMP9, 10 ng/mL of VEGF, or a combination of BMP9 and VEGF. Cells were counted in a Neubauer chamber after 48 hours. Measurements were made under all conditions in triplicate in at least 3 independent experiments.
Cell Growth Assay
Ten-thousand cells were seeded in 24-well plastic plates (Corning, NY). The next day, the medium was changed to M199 with 0.5% FCS, and the cells were treated or not with 10 ng/mL of BMP9, 10 ng/mL of VEGF, or a combination of BMP9 and VEGF and in the absence or the presence of 0.5 μM SF1670. Cells were counted in a Neubauer chamber on 2 occasions (48 and 72 hours). Measurements were made under all conditions in triplicate in at least 3 independent experiments.
Bromodeoxyuridine Proliferation Assay
Fifty-thousand HUVECs were cultured on glass coverslips in 12-well plastic plates. The next day, the medium was changed to M199 without FCS, and the cells were treated or not with 10 ng/mL of BMP9, 10 ng/mL of VEGF, or a combination of BMP9 and VEGF for 20 hours. In parallel, exponential HUVECs (with 20% FCS) were plated for 24 hours and treated or not with 10 ng/mL of BMP9 and in the absence or the presence of 0.5-μM LDN-212854. Bromodeoxyuridine (BrdU; 10 mmol/L; Amersham Pharmacia Biotech, Cambridge, United Kingdom) was added to the culture medium during the last 4 hours. Cells were fixed in 4% paraformaldehyde for 10 minutes at RT, permeabilized for 10 minutes with Tris-buffered saline with Triton (TBS-T; 25 mmol/L Tris-HCl pH 7.4, 150 mmol/L NaCl, 0.5% Triton X-100), blocked with TBS-T containing 2% BSA, and incubated with primary antibody against BrdU (1:100) at 4°C for 16 hours. The following day, cells were washed 3× with TBS-T and incubated with Alexa conjugated secondary antibodies for 2 hours at RT. DAPI (4',6-diamidino-2-phenylindole) was added in the final wash. Specimens were mounted in Mowiol. Cells were visualized in a Nikon-80I microscope.
Western Blotting
Cells were collected and washed twice in cold PBS and lysed for 15 minutes at 4°C in radioimmunoprecipitation assay lysis buffer (10 mmol/L NaF, 40 mmol/L β-glycerophosphate, 200 μM sodium orthovanadate, 0.1 μg/μL benzamidine, 100 μM phenylmethylsulfonyl fluoride, 1 μM pepstatin A, 1 μg/mL leupeptin, 4 μg/mL aprotinin, 1% NP-40, 0.1% SDS, 0.5% sodium deoxycholate in PBS 1X pH 7.4). Insoluble material was removed by centrifugation at 12 000 g for 5 minutes at 4°C. Proteins were separated by SDS-PAGE and electrophoretically transferred to Immobilon-P membranes (Millipore) in 25 mmol/L Tris-HCl, 0.19 mol/L glycine, and 10% methanol. Membranes were blocked in Tris-buffered saline, which is also known as TBS (50 mmol/L Tris, pH 7.4, 150 mmol/L NaCl), containing 5% nonfat dry milk for 1 hour at RT. Blots were incubated with 1:1000 polyclonal rabbit antiphospho-Smad1 
PTEN Activity
HUVECs were starved in M199 without FCS for 16 hours and then pretreated or not with 10 ng/mL of BMP9 for 4 hours and finally treated or not with 10 ng/mL of VEGF for an additional 30 minutes. Cells were collected, washed twice in cold PBS, and lysed for 15 minutes at 4°C in NP-40 lysis buffer (50 mmol/L Tris, 150 mmol/L NaCl, 10% glycerol, 0.1 μg/μL benzamidine, 100 μM phenylmethylsulfonyl fluoride, 1 μM pepstatin A, 1 μg/mL leupeptin, 4 μg/mL aprotinin, 0.2% NP-40, pH 7.4). Insoluble material was removed by centrifugation at 12 000 g for 5 minutes at 4°C. To immunoprecipitate PTEN, 750 µg of total protein was first precleaned by incubation for 4 hours at 4°C on an orbital shaker with 15 μL of protein A-Sepharose beads (GE Healthcare) and 15 μL of protein G-Sepharose beads (GE Healthcare). Beads were then discarded after centrifugation, and lysates were incubated with 2 μL of the rabbit polyclonal anti-PTEN antibody (Cat. 9559; Cell Signaling Technology, Inc) overnight at 4°C on the orbital shaker, with the exception of the negative controls that were incubated without antibody. Then lysates were incubated for 4 hours at 4°C on the orbital shaker with 15 μL of protein A-Sepharose beads (GE Healthcare) and 15 μL of protein G-Sepharose beads (GE Healthcare), previously cleaned with NP-40 buffer. Immunoprecipitates were then collected by centrifugation, washed 3× with NP-40 buffer at 4°C and once with PTEN Reaction buffer (Echelon Biosciences, Salt Lake City, UT). After immunoprecipitation, PTEN phosphatase activity was immediately measured in the bead complex using a PTEN activity ELISA (Cat. K-4700; Echelon Biosciences). PTEN activity was estimated by the percentage conversion from the initial phosphatidylinositol(3,4,5)P 3 to phosphatidylinositol(4,5)P 2 per assay point.
Quantitative Real-Time Polymerase Chain Reaction
Total RNA from HUVECs was extracted using TRIzol Reagent (Ambion, ThermoFisher Scientific). cDNA was obtained from a reverse transcription reaction (High-Capacity cDNA Reverse Transcription Kit; Applied Biosystems, Life Technologies, CA). Realtime polymerase chain reaction of cDNA obtained was performed on a LightCycler instrument (Roche Molecular Biochemicals, Lewes, United Kingdom). After initial incubation at 95°C for 10 minutes, 40 cycles of amplification were performed with denaturation at 95°C for 10 seconds, followed by annealing for 20 seconds (at 64°C) and extension at 72°C for 13 seconds. The ∆C t values were calculated after subtracting the mean C t values of the RPL32 gene from PTEN mean C t values. Results are presented as values of 2 (−∆∆Ct) relative to basal values.
The human-specific primers used were PTEN (5′-GTTTACCGCC AGCATCAAAT-3′ and 5′-CCCCCACTTTAGTGCAC-3′) and the housekeeping gene RPL32 (5′-CAGGGTTCGTAGAAGATTCAA GGG-3′ and 5′-CTTGGAGGAAACATTGTGAGCGATC-3′).
Gene Expression Analysis
Preprocessed and normalized gene expression data from telangiectasial or normal human tissue was obtained from the Gene Expression Omnibus reference GSE53515. 23 The rank-based analysis was based on the Gene Set Expression Analysis 24 tool using standard parameters.
The ranking of expression differences between telangiectasial and normal HHT2 tissue was based on the computed T statistic of paired samples. Two of the analyzed gene sets corresponded to independently curated annotations of the PI3K-AKT-mTOR (mammalian target of rapamycin) signaling pathway (Hallmark PI3K-AKT-MTOR signaling and [Pathway Interaction Database] PI3KCI-AKT, included in Gene Set Expression Analysis MSigDB), and a third one corresponded to genes significantly overexpressed (false discovery rate, <5%) by oncogenic PI3KCA mutations in a nontumorigenic epithelial cell model (GSE33403).
Statistical Analysis
Statistical significance of group differences was determined using 2-tailed Mann-Whitney U tests (*P<0.05, **P<0.01, ***P<0.001, ****P<0.0001). In the case of multiple group analysis, we have used Kruskal-Wallis test to assay differences between groups. Correlation between cutaneous telangiectasia biopsy positivity for pNDRG1 and nosebleed severity measured by the Epistaxis Severity Score was analyzed using 2-tailed Pearson correlation (P<0.01). Analyses were done using GraphPad Prism (v5.0b).
Results
Heterozygous Loss of ALK1 Results in Retinal Vascular Hyperplasia
To gain insight into the molecular mechanism accounting for vascular malformations on loss of ALK1 function in patients with HHT, we investigated vessel growth in postnatal mouse retinas. ALK1 −/− mice die in midgestation, 12,13 so we studied heterozygous ALK1 +/− retinas. Whole-mount IB4-stained ALK1 +/− retinas showed no differences in vascular radial expansion or the number of branch points compared with wild-type littermates' retinas at postnatal days 5 (P5), 7, and 9 ( Figure 1 ; Figure I in the online-only Data Supplement). In contrast, a partial decrease in ALK1 levels resulted in vessel hyperplasia, as indicated by increased vessel width (Figure 1 ). Vessel hyperplasia in ALK1 +/− retinas occurred in capillary areas located above veins at P5, P7, and P9, whereas the effect was only observed in capillary areas located above arteries at P9 (Figure 1 ). Together, these findings indicate that ALK1 signaling limits vessel width in sprouting angiogenesis, but it is not necessary for endothelial cell migration and tip/stalk election. Although ALK1 +/− retinas have a mild vascular phenotype, they partially recapitulate the phenotype of full inactivation of ALK1 in endothelial cells, 25 demonstrating a dose-response effect of ALK1 in endothelial cells.
Coverage by mural cells regulates vessel diameter. Hence, the increase in vessel width induced by ALK1 inhibition could be a consequence of reduced coverage by mural cells. 26, 27 However, immunostaining with desmin-a marker for retinal pericytes-did not reveal any obvious difference between wild-type and ALK1 +/− retinas ( Figure II in the online-only Data Supplement). Next, we examined whether an increase in endothelial cell number could account for the increase in vessel width on heterozygous loss of ALK1. To this end, wild-type and ALK1 +/− retinas were stained with Erg-1/2/3-an endothelial-specific nuclear marker. Surprisingly, no differences were observed in the frequency of endothelial cells located in the inner retinal zone or in the first migratory endothelial cell line (mainly tip cells) 28 ( Figure 2A and 2B) . Conversely, an accumulation of 25% more endothelial cells was observed in the subfront (mainly formed of stalk cells) of ALK1 +/− retinas compared with wild-type retinas. To establish whether this greater number was caused by an increase in endothelial cell proliferation, retinas were costained with Erg-1/2/3 and Edu (a proliferation marker; Figure 2A and 2C). Consistently, no differences were observed in the number of proliferative endothelial cells located in the internal vascular retinal area and in the first migratory endothelial line. Instead, a 41% higher frequency of proliferative endothelial cells was observed in the subfront of ALK1 +/− retinas, indicating that ALK1 signaling restricts endothelial cell proliferation in vivo at the sprouting front.
BMP9 Blocks VEGF-Induced Proliferation in HUVECs
To understand the mechanisms by which ALK1 prevents cell cycle progression in endothelial cells, we used cultured HUVECs and studied the crosstalk between BMP9 and angiogenic signals, such as VEGF. First, we stimulated HUVECs with VEGF, BMP9, or a combination of both, for 48 or 72 hours, followed by assessment of the total number of cells. Although BMP9 alone did not change the growth of HUVECs, VEGF promoted a 37% increase in cell number after 48 hours and a 326% after 72 hours ( Figure 2D ). However, VEGF failed to stimulate cell number in the presence of BMP9. To confirm that BMP9 blocks cell proliferation without stimulating cell death, we measured BrdU incorporation in quiescent HUVECs in the presence of BMP9 and VEGF. As expected, stimulation with VEGF led to a greater degree of BrdU incorporation in HUVECs ( Figure 2E ) compared with nonstimulated conditions. We also found that BrdU incorporation was reduced by BMP9 stimulation in basal and VEGF-stimulated cells. BMP9 addition also reduced cell proliferation in complete medium (20% FCS). In agreement with the negative BMP9-ALK1 role, addition of LDN-212854-an ALK1 inhibitor-increased BrdU incorporation in HUVEC alone and reverted the inhibition caused by BMP9 ( Figure 2E ).
BMP9 Dampens VEGF-Induced Activation of AKT and ERKs
Next, we analyzed the effect of 15-minute or 4-hour BMP9 pretreatment in VEGF-mediated activation of PI3K-AKT, +/− (n=6) retinas at P7. D, Human umbilical vein endothelial cells (HUVECs) were incubated for 48 or 72 h in medium 199 with 0.5% serum, in the presence or absence of 10 ng/mL VEGF (vascular endothelial growth factor), 10 ng/mL BMP (bone morphogenetic protein) 9 or 10 ng/ mL VEGF, and 10 ng/mL BMP9, after which the cell number was counted. Each data point represents the mean of at least 3 independent experiments. E, Bars show quantification of proliferation of quiescent HUVECs plated for 24 h in the absence or presence of 10 ng/mL VEGF, 10 ng/mL BMP9 or 10 ng/mL VEGF, and 10 ng/mL BMP9, or exponential HUVECs (with 20% FCS) plated for 24 h in the absence or presence of 0.5 μM LDN-212854 and in the absence or presence of 10 ng/mL BMP9. Cells were pulsed with bromodeoxyuridine (BrdU) for 4 h and subjected to immunostaining analysis. Results shown are the means of 4 independent experiments. Error bars indicate the standard errors of the mean. Statistical significance of 2-tailed Mann-Whitney U tests: *P<0.05, **P<0.01, ***P<0.001. incubation had no effect on AKT and ERK1/2 activation ( Figure IVA in the online-only Data Supplement). Instead, a 4-hour preincubation with BMP9 blocked basal and VEGFmediated phosphorylation of AKT (in threonine 308 and serine 473) and ERK1/2, without affecting the total amount of AKT or ERK1/2 protein or phosphorylation of VEGFR2 (Figure 3 ). This effect was dose-dependent, with a maximum effect achieved at a dose of 0.5 ng/mL of BMP9 in the absence of VEGF and of 5 ng/mL in the presence of VEGF ( Figure IVC through IVE in the online-only Data Supplement). Moreover, a minimum of 2 hours time of preincubation with BMP9 was necessary to overrule the VEGF-mediated activation of AKT and ERKs ( Figure IV in the online-only Data Supplement). We then sought to determine whether preincubation with VEGF also impaired the BMP9 canonical signaling pathway. However, BMP9-induced phosphoSMAD1/5 and ID1 expression were not altered if the cells had been preincubated with VEGF for 1 hour before adding BMP9 ( Figure V in the online-only Data Supplement). Taken together, our data findings indicate that BMP9/ALK1 fine-tunes VEGF signaling, but this proangiogenic cue has no effect in modulating BMP9 signaling. Our results identify BMP9 as a negative modulator of proangiogenic signals in endothelial cells.
BMP9 Inhibits PI3K Signaling by Increasing PTEN Activity
The PI3K/PTEN axis, 28, 29 but not ERK1/2 signaling, 30 has been shown to regulate endothelial cell proliferation in mouse retina angiogenesis. Furthermore, loss of PTEN in endothelial cells results in vascular hyperplasia similar to that observed in ALK1 +/− retinas. 28 Therefore, we hypothesized that BMP9 fine-tunes PI3K signaling by regulating PTEN. To confirm this, we first measured PTEN phosphatase activity. PTEN was immunoprecipitated from endothelial cells treated or not with BMP9 for 4 hours and additional 30 minutes with VEGF, and PTEN activity was quantified by its capacity to dephosphorylate PI(3,4,5)P 3 to PI(4,5)P 2 . BMP9 treatment promoted a 48% increase in PTEN phosphatase activity, and this effect was independent of the presence or not of VEGF ( Figure 4A ). Next, we measured protein abundance after BMP9 treatment. Our results showed that PTEN amounts were maintained by a 4-hour treatment with BMP9 but increased substantially (86%) Although VEGF failed to stimulate cell number in the presence of BMP9 in nonsilencing control cells, in the absence of PTEN, BMP9 was not able to block VEGF-induced cell proliferation ( Figure 4E ). We confirmed this result by incubating HUVEC with a PTEN inhibitor, SF1670. This compound also blocked the inhibitory effect of BMP9 on VEGF-induced endothelial cell number ( Figure 4F ), further supporting that PTEN activity is necessary to mediate BMP9 effects.
Activation of the PI3K Pathway in Cutaneous Telangiectasia Biopsies of Patients With HHT2
Having identified the mechanism of action of negative regulation by BMP9 signaling on proangiogenic signals, next we aimed to study the status of the PI3K pathway in samples from HHT2-affected individuals. To this end, we first examined publicly available gene expression data from nasal tissue experiments is shown. D, HUVECs were transiently transfected with an unrelated control siRNA (unrelated siRNA) or PTEN siRNA, as described. After 48 h, cells were depleted of growth factors for 16 h. Cells were pretreated or not with 10 ng/mL BMP9 for 4 h, and then stimulated for 30 min in the absence or presence of 10 ng/mL VEGF. Cells were lysed and immunoblotted using the indicated antibodies. A representative blot of 5 independent experiments is shown. E, After transfection with siRNAs, 1×10 4 cells were seeded in 24-well plastic plates in normal medium. The next day, the medium was changed to M199 with 0.5% FCS, and the cells were treated or not with 10 ng/mL of BMP9, 10 ng/mL of VEGF, or a combination of BMP9 and VEGF. After 48 h, the cell number was assessed. Each data point represents the mean of at least 8 independent experiments. F, HUVECs were incubated in medium 199 with 0.5% serum, in the presence or absence of 10 ng/mL VEGF, 10 ng/mL BMP9, 10 ng/mL VEGF, and 10 ng/mL BMP9, and in the absence or presence of 0.5 μM SF1670 PTEN inhibitor. After 72 h, the cell number was counted. Each data point represents the mean of at least 4 independent experiments. Error bars indicate the standard errors of the mean. Statistical significance of 2-tailed Mann-Whitney U tests: *P<0.05, **P<0.01, ***P<0.001.
of HHT2-affected and control individuals (21 and 19, respectively 23 ). Using a rank-based algorithm, 24 a significant bias toward overexpression of genes linked to PI3K/AKT signaling (measured with 3 gene sets) was observed in telangiectasial tissue relative to normal tissue of patients with HHT2 (P values <0.01; Figure 5A ; Table I in the online-only Data Supplement). Significant overexpression of these sets was also observed when comparing data of telangiectasial HHT2 tissue against normal tissue obtained from healthy individuals but not when comparing normal HHT2 against normal tissue of healthy individuals. 23 Next, we analyzed cutaneous telangiectasia biopsies from 6 patients with HHT2 with mutations in the ACVRL1 gene (Table) and from 3 controls. We performed immunohistochemistry for CD34 (an endothelial cell marker), pAKT (S473), pNDRG1 (Thr 346), and pS6 (S240/244); markers of PI3K activation. 31, 32 As shown in Figure 5B and 5C, we found a 53% increase of vessels that were positive for pAKT. Moreover, a low frequency of control vessels were positive for pNDRG1 (3%; Figure 5B and 5D). In contrast, in the telangiectasia cohort, we found a 5-fold greater frequency of vessels that were positive for pNDRG1. Similarly, although endothelial cells from control biopsies were negative for pS6 staining, we found a 7-fold greater frequency of endothelial cells that were positive for pS6 ( Figure 5B and 5E ). Interestingly, we found a statistically significant positive correlation between grade of positivity for pNDRG1 and nosebleed severity measured by the epistaxis severity score (Table; Figure  VII in the online-only Data Supplement).
Patients with HHT present enlarged abnormal vessels with high number of endothelial cells ( Figure 5B ). We asked whether mutations in ALK1 also increased endothelial cell proliferation in vessels from patients with HHT2, as observed in our mouse model. We performed immunohistochemistry for Ki-67-a proliferation marker-in our HHT2 patient group and compared it with controls. Results indicated that the mean proliferation index was 3.3× significantly higher in endothelial cells from telangiectasias of patients with HHT2 than in control vessels (2.3 versus 0.7, respectively; Figure 5B and 5F).
Inhibition of PI3K Prevents Vascular Hyperplasia Induced by Loss of ALK1 Expression
Finally, we examined whether inhibition of PI3K signaling can revert the vascular hyperplasia phenotype induced by heterozygous loss of ALK1 in vivo. To this end, we crossed ALK1 +/− heterozygous animals with a constitutive mouse line in which endogenous p110α/PI3K isoform is converted into kinase-dead protein (hereafter p110α
KD/WT
). 22 Although homozygous p110α KD/KD mice die during embryonic development as a consequence of vascular failure, heterozygous inactivation of p110α results in mild reduction of radial expansion 33 an effect that was maintained in double-heterozygous mutant retinas (ALK1 Figure 6A and 6B) . We validated these results by pharmacological inhibition of PI3K signaling with LY294002-a pan-PI3K inhibitor. Pups were treated with LY294002 at P6 and P7 ( Figure 6C ), and their retinal vasculature was examined at P7. The hyperplasia induced by ALK1 heterozygosity was also rescued by pharmacological inhibition of PI3K activity ( Figure 6D and 6E) . Taken together, these results confirm that BMP9/ALK1 regulates endothelial cell proliferation in vivo, at least partially, by inhibiting PI3K/AKT signaling.
Discussion
In the present study, we demonstrate that BMP9/ALK1 promotes vascular quiescence by inhibiting PI3K/AKT and ERK MAPK activation and show that loss of ALK1 causes overstimulation of these signaling hubs. In recent years, the role of the BMP9-BMPRII-ALK1-endoglin-SMAD1/5 axis in endothelial cells has begun to be clarified. 34, 35 Indeed, BMP9/ALK1 inhibits cell proliferation and migration in cultured endothelial cells 10, 36, 37 and in zebrafish. 38 In mice, the blockade of BMP9/ALK1 signaling by anti-BMP9 neutralizing antibody or by injection of the extracellular domain of ALK1 increases vascular density. 39 Also, in mice, depletion of ALK1 specifically in endothelial cells results in AVMs as a result of increased endothelial cell proliferation. 25, [40] [41] [42] Our results in vitro and in vivo confirm this antiproliferative role of BMP9/ALK1 in sprouting angiogenesis. Our work also reveals that during vessel growth, BMP9/ALK1 signaling does not regulate cell proliferation in all angiogenic endothelial cells in vivo but, rather, specifically in those cells located at the sprouting. Activation of Notch at the sprouting front results in stalk cell cycle arrest 28 through a similar mechanism to that of BMP9/ALK1 (see below). It is, therefore, reasonable to speculate that Notch and BMP9/ALK1 cooperate to restrain stalk cell proliferation at this specific location. In keeping with this, previous results have shown that ALK1, through SMAD1/5 43, 44 or SMAD2/3 activation, 45 cooperates with the Dll4/Notch pathway to induce the stalk cell phenotype.
Our in vitro and in vivo findings place PI3K/AKT and ERK MAPK at the center of the BMP9/ALK1 antiproliferative response ( Figure IX in the online-only Data Supplement). Our results using HUVECs as a model have shown that BMP9/ ALK1 blocks the PI3K/AKT and ERK activation induced by VEGF. In contrast, we have found that pharmacological inhibition of PI3K is sufficient to abolish ALK1-induced vascular hyperplasia in vivo. This observation, together with the fact that inhibitors of MEK1 (mitogen-activated protein kinase kinase)-ERKs in vivo fail to block endothelial cell proliferation in wild-type retinal angiogenesis, 30 suggests that limiting PI3K signaling is the principal mechanism by which ALK1 stimulates vascular quiescence in vivo. The PI3K/AKT pathway stimulates cell proliferation, migration, and survival in endothelial cells downstream of many angiogenic cues. 28, 46 We have identified BMP1/ALK1 as a new upstream signal that regulates PI3K activity in sprouting angiogenesis. Although most of the angiogenic cues activate the PI3K signaling pathway to execute their biological actions, we have found that BMP9/ ALK1 represses this signaling cascade by stimulating the activity of PTEN-the principal phosphatase that counteracts this signaling pathway in endothelial cells. 46 PTEN is a lipid and protein phosphatase whose function is regulated at multiple levels, including mRNA and protein expression, subcellular localization, and direct regulation of its phosphatase activity by post-translational modifications, such as phosphorylation, ubiquitination, and protein interactions. 47, 48 We have identified that regulation of PTEN by BMP9/ALK1 in endothelial cells is also multifactorial. First, the observation that BMP9/ALK1 dampens AKT phosphorylation after a 2-hour incubation with BMP9 suggests a direct regulation of PTEN catalytic activity. Recently, Ola et al 47 have described that the phosphorylated Ser380/Thr382/Thr383-inactive form of PTEN was decreased in HUVECs and mLECs endothelial cells stimulated for 2 hours with BMP9. 42 Second, we have clear evidence that stimulation of endothelial cells by BMP9/ALK1 increases mRNA and protein abundance of PTEN. This is not unique to BMP9/ALK1 because we have previously shown that Dll4/Notch also stimulates PTEN expression to block stalk cell proliferation. 28 Given the previously identified crosstalk between ALK1 and Notch, the increase in PTEN amount on BMP9 stimulation could be explained by an indirect response induced by Notch. However, we cannot rule out a direct effect of SMADs on PTEN promoter on BMP9 stimulation. PTEN expression is also tightly regulated by miR, including in endothelial cells. Indeed, VEGF restrains PTEN expression amount by increasing the expression of the miR-17 to 92 cluster in endothelial cells. 49 Therefore, it is also possible that BMP9/ALK1 regulates PTEN abundance by inhibiting negative regulators of its expression. Taken together, we have identified a previously unknown interaction of BMP9/ ALK1 and PTEN in endothelial cells, which seems critical to the pathogenesis of loss of ALK1 expression. HHT is mainly caused by heterozygous mutations in ENG 17 or ALK1 (ACVRL1) 18 genes. These are loss-of-function mutations that lead to reduced BMP9/ALK1/endoglin/ SMAD1/5 signaling and enhanced response to angiogenic cues and thereby to excessive abnormal angiogenesis.
14 The telangiectasia arises from a postcapillary hyperplastic venule that fuses directly with an arteriole, resulting in an arteriovenous shunt in the small-sized vessels. 15 The role of endothelial cell proliferation in the development of these enlarged abnormal vessels in HHT has not been studied in deep. Hashimoto et al 50 found higher Ki-67 index for endothelial cells of sporadic brain AVMs compared with endothelial cells from control cortical vessels. In the case of HHT, Du et al 51 found increased endothelial cell proliferation in a resection of intracranial AVM in a 26-day-old boy with HHT. Our data obtained in patients, as well as the results obtained in mouse models, confirm that AVMs and increased endothelial cell proliferation are interrelated, suggesting that the AVM phenotype in patients with HHT arises, at least in part, from an aberrant endothelial cell proliferation. In line with this stimulation of VEGF signaling, a promitogenic factor for endothelial cells is required for the development of HHT. Indeed, although heterozygous ALK1 mice do not develop AVM, intracranial injection of VEGF in ALK1 +/− mice leads to abnormal AVM-like structures, 52 and blocking VEGF attenuates these vascular lesions. 53 This is in agreement with the observation that PI3K/AKT is a key signaling hub downstream of VEGF in angiogenesis. 46 Our results show for first time an overstimulation of the PI3K pathway on vessels of patients with HHT2. We found a statistically significant relationship between PI3K-activated vessels in the finger telangiectasia biopsy and the severity of nosebleeds measured by the epistaxis severity score. This association suggests a more intense development of systemic telangiectasias (ie, cutaneous or in nasal mucosa) when PI3K signaling is active. It is of particular note that we and others have found that the majority of venous malformations-the most common form of vascular malformation-are driven by constitutively activating PI3K signaling. 29, 54 Taken together, the results suggest that overactivation of PI3K signaling is a common characteristic in vascular malformations. By using a mouse model for HHT, our findings also show that the genetic or pharmacological inhibition of PI3K prevents ALK1-induced vascular hyperplasia in retinas. Our findings corroborate results in the study by Ola et al 42 in which homozygous deletion of ALK1 in endothelial cells results in arterial venous shuts also by upregulating PI3K signaling. These results suggest that PI3K inhibitors could be used as an alternative therapeutic approach to treat patients with HHT. Inhibition of the PI3K signaling in the vasculature could, therefore, prevent the development of telangiectasias and improve nose bleeds in patients with HHT. In keeping with this observation, a study has reported a clinical case of an HHT2 patient diagnosed with serous ovarian cancer who showed a drop in the frequency of epistaxis on treatment with a PI3K inhibitor (BKM120). 55 Therefore, we propose that the use of PI3K or AKT inhibitors should be considered as alternative pharmacological strategies for treating patients with HHT.
